|
|
|
|
| LEADER |
02795nam a2200325 u 4500 |
| 001 |
EB000943707 |
| 003 |
EBX01000000000000000737297 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
150223 r ||| eng |
| 100 |
1 |
|
|a Shekelle, Paul G.
|
| 245 |
0 |
0 |
|a Treatment of metastatic non-small cell lung cancer
|h Elektronische Ressource
|b a systematic review of comparative effectiveness and cost-effectiveness
|c prepared for, Department of Veterans Affairs, Veterans Health Administration, Quality Enhancement Research Initiative, Health Services Research & Development Service ; prepared by, Evidence-based Synthesis Program (ESP) Center, West Los Angeles VA Medical Center ; principal investigators, Paul G. Shekelle, Alicia R. Maher ; research associates, Isomi M. Miake-Lye, Jessica M. Beroes
|
| 260 |
|
|
|a Washington, DC
|b Department of Veterans Affairs, Health Services Research & Development Service
|c [2012], 2012
|
| 300 |
|
|
|a 1 PDF file (iv, 82 pages)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Comparative Effectiveness Research
|
| 653 |
|
|
|a Lung Neoplasms / drug therapy
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Carcinoma, Non-Small-Cell Lung / drug therapy
|
| 700 |
1 |
|
|a Ruelaz Maher, Alicia
|e [author]
|
| 710 |
2 |
|
|a United States
|b Department of Veterans Affairs
|
| 710 |
2 |
|
|a West Los Angeles VA Medical Center
|b Evidence-Based Synthesis Program Center
|
| 710 |
2 |
|
|a Quality Enhancement Research Initiative (U.S.)
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Evidence-based synthesis program
|
| 500 |
|
|
|a Title from PDF cover. - "October 2012."
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK153078
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Lung cancer is the leading cause of cancer death in both men and women in the United States, and male Veterans seeking care at VA hospitals have a much higher age-specific incidence of lung cancer than males in the general population. The personal and economic significance of lung cancer has led to a vast research endeavor to try and identify new and more effective treatments. Most patients with lung cancer are diagnosed when the cancer is already advanced (stage IIIB or IV), and they are no longer candidates for surgical resection. Small cell lung cancer and non-small cell lung cancer (NSCLC) are different diseases in terms of treatment. Until recently, all therapies for advanced NSCLC were based on their cytotoxic properties. In the last few years, several novel agents aimed at specific molecular targets have been developed. This review was requested to evaluate the current evidence on the effectiveness and cost-effectiveness of treatments for advanced lung cancer
|